Publications

Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models

Jeffrey W Eaton, Nicolas A Menzies, John Stover, Valentina Cambiano, Leonid Chindelevitch, Anne Cori, Jan A C Hontelez, Salal Humair, Cliff C Kerr, Daniel J Klein, Sharmistha Mishra, Kate M Mitchell, Brooke E Nichols, Peter Vickerman, Roel Bakker, Till Bärnighausen, Anna Bershteyn, David E Bloom, Marie-Claude Boily, Stewart T Chang, Ted Cohen, Peter J Dodd, Christophe Fraser, Chaitra Gopalappa, Jens Lundgren, Natasha K Martin, Evelinn Mikkelsen, Elisa Mountain, Quang D Pham, Michael Pickles, Andrew Phillips, Lucy Platt, Carel Pretorius, Holly J Prudden, Joshua A Salomon, David A M C van de Vijver, Sake J de Vlas, Bradley G Wagner, Richard G White, David P Wilson, Lei Zhang, John Blandford, Gesine Meyer-Rath, Michelle Remme, Paul Revill, Nalinee Sangrujee, Fern Terris-Prestholt, Meg Doherty, Nathan Shaffer, Philippa J Easterbrook, Gottfried Hirnschall, Timothy B Hallett

The Lancet Global Health. 2014 Jan; 2(1).

Cost-effectiveness of tenofovir gel in urban South Africa: model projections of HIV impact and threshold product prices

Fern Terris-Prestholt, Anna M. Foss, Andrew P. Cox, Lori Heise, Gesine Meyer-Rath, Sinead Delany-Moretlwe, Thomas Mertenskoetter, Helen Rees, Peter Vickerman, Charlotte H. Watts

BMC Infectious Diseases. 2014 Jan; 14(14).

Retention in Care and Outpatient Costs for Children Receiving Antiretroviral Therapy in Zambia: A Retrospective Cohort Analysis

Callie A. Scott, Hari Iyer, Deophine Lembela Bwalya, Kelly McCoy, Gesine Meyer-Rath, Crispin Moyo, Carolyn Bolton-Moore, Bruce Larson, and Sydney Rosen

PLoS ONE. 2013 Jun; 8(6).

Diagnosing Xpert MTB/RIF-negative TB: Impact and cost of alternative algorithms for South Africa

K Schnippel, G Meyer-Rath, L Long, W S Stevens, I Sanne, S Rosen

The South African Medical Journal. 2013 Feb; 103(2).

Cost and Outcomes of Paediatric Antiretroviral Treatment in South Africa

Gesine Meyer-Rath, Alana Brennan, Lawrence Long, Buyiswa Ndibongo, Karl Technau, Harry Moultrie, Lee Fairlie, Ashraf Coovadia and Sydney Rosen

AIDS 2012. 2013 Jan; 14(27):243-250.

Rates and Cost of Hospitalization Before and After Initiation of Antiretroviral Therapy in Urban and Rural Settings in South Africa

Gesine Meyer-Rath, Alana T. Brennan, Matthew P. Fox, Tebogo Modisenyane, Nkeko Tshabangu, Lerato Mohapi, Sydney Rosen, and Neil Martinson

JAIDS. 2013 Jan; 62(3):322-328.

Cost and Resource Use of Patients on Antiretroviral Therapy in the Urban and Semiurban Public Sectors of South Africa

Gesine Meyer-Rath, MD, Alec Miners, PhD, Andreia C. Santos, PhD, Ebrahim Variava, MD, and Willem Daniel Francois Venter, MD

JAIDS. 2012 Nov; 61(3):25-32.

Scaling up Xpert MTB⁄RIF technology: the costs of laboratory vs. clinic-based roll-out in South Africa

Kathryn Schnippel, Gesine Meyer-Rath, Lawrence Long, William MacLeod, Ian Sanne, Wendy S. Stevens and Sydney Rosen

Tropical Medicine and International Health. 2012 Jun; 00(00):1-10.

The Impact and Cost of Scaling up GeneXpert MTB/RIF in South Africa

Gesine Meyer-Rath, Kathryn Schnippel, Lawrence Long, William MacLeod, Ian Sanne, Wendy Stevens, Sagie Pillay, Yogan Pillay, Sydney Rosen

PLoS ONE. 2012 May; 7(5):1-11.

The Incremental Cost Of Introducing Xpert® MTB/RIF into the South African National Tuberculosis Programme

Meyer-Rath G., Bistline K., Long L., MacLeod W., Sanne I., Stevens W., Rosen S.

Johannesburg, South Africa; Boston, MA: Health Economics and Epidemiology Research Office, Wits Health Consortium, University of the Witwatersrand (HE2RO); 2011 Jul.

Total Cost and Potential Cost Savings of the National Antiretroviral Treatment (ART) Programme in South Africa 2010 to 2017. Abstract 16112

Meyer-Rath G., Brennan A., Long L., Rosen S., Pillay Y., Johnson L., Mbengashe T., Dlamini N., Fox M.P.

18th International AIDS Conference; 2010 Jul 18; Vienna.

Survival in Care and CD4 Cell Count Gain on First-line ART Depend on Prior CD4 Cell Count and Time on Treatment: Evidence From a Large South African Cohort. Abstract Z-184

Meyer-Rath G., Brennan A., Long L., Rosen S.B., Fox M.P.

17th Conference on Retroviruses and Opportunistic Infections (CROI); 2010 Feb 1; San Francisco.

Good Treatment Outcomes among Foreigners Receiving Antiretroviral Therapy in Johannesburg, South Africa

McCarthy K., Chersich M. F., Vearey J., Meyer-Rath G., Jaffer A., Simpwalo S., Venter W. D.

Int J STD AIDS. 2009 Dec; 20(12):858-62.